







A**B****C****Durvalumab****D****Durvalumab****E****Placebo****F****Placebo**

Supplementary Figure S4: Joint relationship of TMB and TILs with pCR in GeparNuevo

- A) Scatter plot of TMB and TILs in pretreatment biopsies of GeparNuevo patients coloured by response. The cutoff for “lymphocyte predominant breast cancer” (LBPC, $\geq 60\%$ TILs) and the upper tertile of TMB are given by dashed vertical and horizontal lines, respectively.
- B) pCR rates in percentages and 95% confidence intervals (CI) in subgroups defined by the cutoffs given as dashed lines in (A).
- C) Scatter plot of TMB and TILs in pretreatment biopsies of patients from the GeparNuevo durvalumab arm coloured by response. The LPBC cutoff ($\geq 60\%$ TILs) and the upper tertile of TMB are given by dashed vertical and horizontal lines, respectively.
- D) pCR rates in percentages and 95% confidence intervals (CI) in subgroups defined by the cutoffs given as dashed lines in (C).
- E) Scatter plot of TMB and TILs in pretreatment biopsies of patients from the GeparNuevo placebo arm coloured by response. The LPBC cutoff ($\geq 60\%$ TILs) and the upper tertile of TMB are given by dashed vertical and horizontal lines, respectively.
- F) pCR rates in percentages and 95% confidence intervals (CI) in subgroups defined by the cutoffs given as dashed lines in (E).